The Authority noted in its scientific opinion that according to the study of Myers et al., 2006 [Myers SP, Cheras PA, Brooks L and O’Connor J, 2006, unpublished. Study on the Safety and Efficacy of Sylvan Red Yeast Rice in Adults with Primary Hypercholesteremia.], the content of monacolin K in 2,4 g of SYLVAN BIO red yeast rice should have been higher than 4,08 mg. Upon a request from the Authority, the applicant clarified that the red yeast rice preparation used in that study complied with the specifications provided for SYLVAN BIO red yeast rice, and that, taking into account all the active forms, 2,4 g of SYLVAN BIO red yeast rice contained 8,96 mg of monacolin K. The Authority considered that this study, with some methodological limitations, showed an effect of monacolin K in SYLVAN BIO red yeast rice on blood LDL-cholesterol concentrations, at doses of about 9 mg per day.
Recital 8, Regulation (EU) 2024/2063
In forcesince 30 Jul 2024